Increased ERCC Expression Correlates w ith Improved Outcome of Patients T reated w ith C isplatin as an A djuvant Therapy for Curatively Resected Gastric Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: It has been reported that the overexpression of the excision repair cross-complementing 1 (ERCC1) gene, which is essential for the repair of cisplatin (CDDP)- DNA adducts, negatively influences the effectiveness of CDDP-based therapy for primary gastric cancer. We investigated whether the ERCC1 expression was associated with survival for gastric cancer patients in an adjuvant setting. Materials and Methods: We retrospectively analyzed 44 patients who were diagnosed with stage II or higher disease after undergoing curative resection and they had also received cisplatin-based chemotherapy. The ERCC1 expression was examined by performing immunohistochemical (IHC) staining, and this was divided into two groups according to the percentage of IHC staining of the tumor cell nuclei (negative: 10% or less, positive: more than 10%). Results: Among the 44 patients (ERCC1-negative/ERCC1-positive group=16/28), 32 patients were male and their median age was 52 years. There was no difference for the baseline characteristics of the two groups. The median follow-up duration was 41 months. The median disease-free survival (DFS) and the overall survival (OS) for the ERCC1-positive group were significant higher than those of the ERCC1-negative group (DFS: 40.4 vs. 14.6 months, p=0.02, OS: undefined vs. 20.4 months, p=0.008). Conclusion: The overall survival in gastric cancer patients who received cisplatin-based adjuvant chemotherapy after a curative resection is higher in those patients showing the overexpression of the ERCC1 gene. However, prospective studies using the ERCC1 gene expression as a prognostic marker for the DNA repair activity are needed. (Cancer Res Treat. 2006;38:19-24)
Abstract
Purpose: It has been reported that the overexpression of the excision repair cross-complementing 1 (ERCC1) gene, which is essential for the repair of cisplatin (CDDP)- DNA adducts, negatively influences the effectiveness of CDDP-based therapy for primary gastric cancer. We investigated whether the ERCC1 expression was associated with survival for gastric cancer patients in an adjuvant setting. Materials and Methods: We retrospectively analyzed 44 patients who were diagnosed with stage II or higher disease after undergoing curative resection and they had also received cisplatin-based chemotherapy. The ERCC1 expression was examined by performing immunohistochemical (IHC) staining, and this was divided into two groups according to the percentage of IHC staining of the tumor cell nuclei (negative: 10% or less, positive: more than 10%). Results: Among the 44 patients (ERCC1-negative/ERCC1-positive group=16/28), 32 patients were male and their median age was 52 years. There was no difference for the baseline characteristics of the two groups. The median follow-up duration was 41 months. The median disease-free survival (DFS) and the overall survival (OS) for the ERCC1-positive group were significant higher than those of the ERCC1-negative group (DFS: 40.4 vs. 14.6 months, p=0.02, OS: undefined vs. 20.4 months, p=0.008). Conclusion: The overall survival in gastric cancer patients who received cisplatin-based adjuvant chemotherapy after a curative resection is higher in those patients showing the overexpression of the ERCC1 gene. However, prospective studies using the ERCC1 gene expression as a prognostic marker for the DNA repair activity are needed. (Cancer Res Treat. 2006;38:19-24)
참고문헌 (19)
- "2001 Annual report of the korea central cancer registry: based on registered data from 134 hospitals", 36, pp.19~30 (2004)
- "Wagman gastric cancer. Cancer management", pp.259~72 (2004), CMP media LLC
- "Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode", 205, pp.698~9 (1965)
- "Diaminodichloroplatinum: a phase I study showing responses in testicular and other tumors", 33, pp.1219~25 (1974)
- "A systematic overview of chemotherapy effects in gastric cancer", 40, pp.309~26 (2001)
- "Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomized trials", 35, pp.1059~64 (1999)
- "Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials", 11, pp.1441~7 (1993)
- "Effect of ERCC-1 overexpression on sensitivity of Chinese hamster ovary cells to DNA damaging agents", 53, pp.3237~40 (1993)
- "Cisplatin sensitivity", resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3, 1993, pp.14, 2177~80
- "ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy", 16, pp.309~16 (1998)
- "Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer", 8, pp.2286~91 (2002)
- "ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells", 89, pp.453~7 (2000)
- "Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer", 65, pp.130~7 (1997)
- "ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy", 19, pp.4298~304 (2001)
- "Manual for staging of cancer. american joint committee on cancer", pp.81~7 (1997), JB Lippincott
- "ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer (NSCLC)", 127, pp.978~83 (2005)
- "What is the best way to assess microsatellite instability status in colorectal cancer?", 28, pp.1553~9 (2004)
- "XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy", 22, pp.2594~601 (2004)
- "Decreased pyruvate kinase M2 activity linked to cisplatin resistance in human gastric carcinoma cell lines", 108, pp.532~9 (2004)